

WuXi Biology

Global Drug Discovery Enabler

- **Comprehensive** discovery and translational biology centers, with **~3,000** experienced scientists and global footprints in **9** sites
- Early discovery screening platform, providing diverse **hit finding solutions** and **high throughput hit optimization solutions** such as DEL/HTS/HCS/ASMS/FBDD*/Display/virtual screening and Direct-to-Biology, supported by informatics and data sciences
- **Thousands** of validated, 'ready to go', *in vitro* assays and *in vivo* models enabling discovery biology for comprehensive target classes, therapeutic areas and modalities
- Extensive **Oncology, Immunology, Infectious Disease, Inflammation, Neuroscience, Rare disease and Metabolic Disease indication**, offering an end-to-end service from discovery, through optimization and into clinical development
- **AAALAC** accredited and **BSL-2** certified on multiple sites
- Pathology and **CAP-certified** FACS capabilities supporting clinical biomarker services

Services and Solutions

Early Discovery

- New target discovery and mechanistic study
- Protein production and structural biology
- High throughput hit optimization: D2B platform
- Screening and hit identification: DEL/HTS/HCS/ASMS/FBDD/Display/VS and libraries for small molecules, covalent, peptides, TPD and macrocycles

Lead Optimization

- *In vitro* biochemistry and cell biology
- Cell panel screening
- MOA studies
- Radiometric assays
- Clinical biomarker development and validation

In Vivo Pharmacology

- Comprehensive *in vivo* disease model collection
- Targeted oncology and immuno-oncology
- Drug resistance and other novel models of higher translational value
- Tumor model database

By the Numbers



~3,000 employees worldwide



9 in **3**
facilities countries



Entrusted by







top 15

global pharmaceutical companies













1800+
customers worldwide

Enabling discovery for all modalities

-  Small molecules
-  Peptides
-  Oligonucleotides
-  Bi-functional molecules, e.g. ADC/PDC/POC/TPD*
-  Vaccines
-  Cell Therapy

Expertise in all major disease areas


- | | |
|--|---|
|  Oncology & Immunology |  Cardiovascular Diseases |
|  Metabolic Diseases |  Digestive System |
|  Central Nervous System |  Respiratory Diseases |
|  Infectious Diseases |  Renal Disorders |
|  Hepatology |  Ophthalmology |

A Global Footprint

CHINA



Shanghai (WGQ)



Shanghai (Zhangjiang)



Suzhou




Nantong



Chengdu

UNITED STATES



San Diego



Cranbury



Boston / Natick

GERMANY



Munich



Contact


USA

 mahnaz_arjomand@wuxiapptec.com

 +1 415 755 3735


EU/UK/Israel

 dave_madge@wuxiapptec.com

 +44 7803 124321


China/Singapore/Australia

 xu_longji@wuxiapptec.com

 +86 185 0210 0621

Japan

 fumio_ito@wuxiapptec.com

 +81 75 315 1044

Korea

 sycho@wuxiapptec.com

 +82 31 724 2861



WuXi Biology website



LinkedIn